A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc

Trial Profile

A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Expanded access
  • Sponsors Pfizer; ViiV Healthcare
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Aug 2011 New source identified and integrated (European Clnincal Trials Database).
    • 01 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top